Divi Cornec1, Valérie Devauchelle-Pensec1, Xavier Mariette2, Sandrine Jousse-Joulin1, Jean-Marie Berthelot3, Aleth Perdriger4, Xavier Puéchal5, Véronique Le Guern5, Jean Sibilia6, Jacques-Eric Gottenberg6, Laurent Chiche7, Eric Hachulla8, Pierre Yves Hatron8, Vincent Goeb9, Gilles Hayem10, Jacques Morel11, Charles Zarnitsky12, Jean Jacques Dubost13, Philippe Saliou14, Jacques Olivier Pers15, Raphaèle Seror2, Alain Saraux1. 1. Centre Hospitalier Universitaire de la Cavale Blanche, and EA 2216, INSERM ESPRI, ERI29, Université de Brest, LabEx IGO, Brest, France. 2. Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, INSERM U1184, Université Paris-Sud, Le Kremlin Bicêtre, France. 3. Hôtel-Dieu, Centre Hospitalier Universitaire Nantes, Nantes, France. 4. Centre Hospitalier Universitaire, Hôpital Sud, Rennes, France. 5. Hôpital Cochin, Paris, France. 6. Hôpitaux Universitaires de Strasbourg and Université de Strasbourg, Strasbourg, France. 7. Hôpital Européen, Marseille, France. 8. Hôpital Claude Huriez and Université Lille Nord-de-France, Lille, France. 9. Centres Hospitaliers Régionaux Universitaires de Amiens, Amiens, France. 10. Centre Hospitalier Universitaire Ambroise Paré, Boulogne, France. 11. Centre Hospitalier Universitaire Lapeyronie, Montpellier, France. 12. Centre Hospitalier J. Monod, Montivilliers, France. 13. Hôpital Gabriel Montpied, Clermont-Ferrand, France. 14. Centres Hospitaliers Régionaux Universitaires Morvan, Brest, France. 15. EA 2216, INSERM ESPRI, ERI29, Université de Brest, LabEx IGO, and Centre Hospitalier Universitaire Morvan, and EA 2216, Université Bretagne Occidentale, Brest, France.
Abstract
OBJECTIVE: To identify the principal determinants of health-related quality of life (HRQOL) impairment in patients with active primary Sjögren's syndrome (SS) participating in a large therapeutic trial, Tolerance and Efficacy of Rituximab in Primary Sjögren's Syndrome (TEARS). METHODS: At the inclusion visit for the TEARS trial, 120 patients with active primary SS completed the Short Form 36 health survey (SF-36), a validated HRQOL assessment tool. Univariate then multivariate linear regression analyses were used to assess associations linking SF-36 physical and mental components to demographic data, patient-reported outcomes (symptom intensity assessments for dryness, pain, and fatigue, including the European League Against Rheumatism [EULAR] Sjögren's Syndrome Patient Reported Index [ESSPRI]), objective measures of dryness and autoimmunity, and physician evaluation of systemic activity (using the EULAR Sjögren's Syndrome Disease Activity Index [ESSDAI]). RESULTS: SF-36 scores indicated marked HRQOL impairments in our population with active primary SS. Approximately one-third of the patients had low, moderate, and high systemic activity according to the ESSDAI. ESSPRI and ESSDAI scores were moderately but significantly correlated. The factors most strongly associated with HRQOL impairment were patient-reported symptoms, best assessed using the ESSPRI, with pain and ocular dryness intensity showing independent associations with HRQOL. Conversely, systemic activity level was not associated with HRQOL impairment in multivariate analyses, even in the patient subset with ESSDAI values indicating moderate-to-high systemic activity. CONCLUSION: The cardinal symptoms of primary SS (dryness, pain, and fatigue, best assessed using the ESSPRI) are stronger predictors of HRQOL impairment than systemic involvement (assessed by the ESSDAI) and should be used as end points in future therapeutic trials focusing on patients' well-being. New consensual and data-driven response criteria are needed for primary SS studies.
OBJECTIVE: To identify the principal determinants of health-related quality of life (HRQOL) impairment in patients with active primary Sjögren's syndrome (SS) participating in a large therapeutic trial, Tolerance and Efficacy of Rituximab in Primary Sjögren's Syndrome (TEARS). METHODS: At the inclusion visit for the TEARS trial, 120 patients with active primary SS completed the Short Form 36 health survey (SF-36), a validated HRQOL assessment tool. Univariate then multivariate linear regression analyses were used to assess associations linking SF-36 physical and mental components to demographic data, patient-reported outcomes (symptom intensity assessments for dryness, pain, and fatigue, including the European League Against Rheumatism [EULAR] Sjögren's Syndrome Patient Reported Index [ESSPRI]), objective measures of dryness and autoimmunity, and physician evaluation of systemic activity (using the EULAR Sjögren's Syndrome Disease Activity Index [ESSDAI]). RESULTS: SF-36 scores indicated marked HRQOL impairments in our population with active primary SS. Approximately one-third of the patients had low, moderate, and high systemic activity according to the ESSDAI. ESSPRI and ESSDAI scores were moderately but significantly correlated. The factors most strongly associated with HRQOL impairment were patient-reported symptoms, best assessed using the ESSPRI, with pain and ocular dryness intensity showing independent associations with HRQOL. Conversely, systemic activity level was not associated with HRQOL impairment in multivariate analyses, even in the patient subset with ESSDAI values indicating moderate-to-high systemic activity. CONCLUSION: The cardinal symptoms of primary SS (dryness, pain, and fatigue, best assessed using the ESSPRI) are stronger predictors of HRQOL impairment than systemic involvement (assessed by the ESSDAI) and should be used as end points in future therapeutic trials focusing on patients' well-being. New consensual and data-driven response criteria are needed for primary SS studies.
Authors: Guillermo Carvajal Alegria; Pierre Gazeau; Sophie Hillion; Claire I Daïen; Divi Y K Cornec Journal: Clin Rev Allergy Immunol Date: 2017-10 Impact factor: 8.667
Authors: Luiz A Gueiros; Katherine France; Rachael Posey; Jacqueline W Mays; Barbara Carey; Thomas P Sollecito; Jane Setterfield; Sook Bin Woo; Donna Culton; Aimee S Payne; Giovanni Lodi; Martin S Greenberg; Scott De Rossi Journal: Oral Dis Date: 2019-06 Impact factor: 3.511
Authors: Giuliana Maria Concetta La Paglia; Olga Sanchez-Pernaute; Alessia Alunno; Maria José Martínez-Becerra; Fredeswinda Romero-Bueno; Sheila Recuero; Pablo Eder Borges; Ignacio Mahillo-Fernández; Jesús Garrido; Roberto Gerli; Gabriel Herrero-Beaumont; Esperanza Naredo Journal: Clin Rheumatol Date: 2019-11-01 Impact factor: 2.980
Authors: Elisabeth Mæland; Samira T Miyamoto; Daniel Hammenfors; Valeria Valim; Malin V Jonsson Journal: Front Immunol Date: 2021-06-25 Impact factor: 7.561